Please login to the form below

Not currently logged in
Email:
Password:

PCSK9

This page shows the latest PCSK9 news and features for those working in and with pharma, biotech and healthcare.

US insurers can peg access to ICER value reviews

US insurers can peg access to ICER value reviews

Founded in 2005, ICER regularly publishes cost-effectiveness guidance on medicines and over the years has shot down a number of new drugs, including PCSK9-targeting cholesterol drugs from Amgen and

Latest news

  • Dupixent bounce-back helps stem diabetes declines at Sanofi Dupixent bounce-back helps stem diabetes declines at Sanofi

    Another Regeneron-partnered drug – and another key component for Sanofi’s specialty medicines drive – is cholesterol-lowering PCSK9 inhibitor Praluent (alirocumab), and while sales rose 55% year-on-year to 62m ... At the moment, Sanofi is losing

  • Daily Brief: Amgen offers Repatha deals in Europe, will Persephone slash Herceptin use? Daily Brief: Amgen offers Repatha deals in Europe, will Persephone slash Herceptin use?

    This puts it ahead of its fellow PCSK9 product and rival, however Sanofi and Regeneron unveiled strong strong cardiovascular outcomes data from their ODYSSEY trial in combination with the huge cut ... However, the majority of patients in Europe who could

  • Esperion craters as deaths mar atherosclerosis drug study Esperion craters as deaths mar atherosclerosis drug study

    Esperion is hoping to position bempedoic as a once-daily, oral alternative to PCSK9 inhibitor such as Amgen’s Repatha (evolocumab) and Sanofi/Regeneron’s Praluent (alirocumab), which are given by ... Esperion recently reported phase II data showing

  • Segmentation, evolved Segmentation, evolved

    Along with results from its Odyssey Outcomes trial, Sanofi said that it plans to offer discounts of up to 69% to encourage payers to expand the use of the PCSK9 inhibitor. ... Research by Amgen, which has a PCSK9 called Repatha, suggests that two-thirds

  • Sanofi, Regeneron offer price cut for cholesterol drug Praluent Sanofi, Regeneron offer price cut for cholesterol drug Praluent

    The offer has been made just after the presentation of the large-scale ODYSSEY OUTCOMES at the American College of Cardiology (ACC) meeting in Orlando, which showed that adding PCSK9 inhibitor ... Both Praluent and Amgen’s rival PCSK9 inhibitor Repatha

More from news
Approximately 16 fully matching, plus 64 partially matching documents found.

Latest Intelligence

  • Astellas: Ten years young Astellas: Ten years young

    With the partners gearing up to launch Amgen's PCSK9 therapy for hypercholesterolemia - a class of drugs that is top of many peoples' minds - it's an approach that seems to

  • Pharma deals in September 2015 Pharma deals in September 2015

    Amgen's busy month (part 2). Following FDA approval for its novel PCSK9 treatment for “ bad cholesterol”, Amgen is moving onto tackle dyslipidemia, an asymptomatic disease in which serum lipid levels

  • Going the distance Going the distance

    Looking to the second half of this year and Sanofi is aiming for a Q3 launch for its new PCSK9 cardiovascular disease management drug Praluent (alirocumab), which comes from its collaboration

  • Pharma deals during November 2014 Pharma deals during November 2014

    In July, BioMarin sold its PRV to Regeneron for $68m to expedite filing of its cholesterol drug, the PCSK9 inhibitor alirocumab, being developed in partnership with Sanofi.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Transforming healthcare outsourcing. From small beginnings in 1997, Ashfield has grown rapidly into an international healthcare services organisation. By anticipating...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics